Back to Journals » Clinical Ophthalmology » Volume 14

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

Authors Radcliffe N, Berdahl J, Ibach M, Schweitzer J, Levine J, McCafferty S

Received 28 May 2020

Accepted for publication 22 July 2020

Published 10 August 2020 Volume 2020:14 Pages 2245—2253


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Video abstract of "Greater latanoprost IOP reduction measured by Goldmann tonometry" [ID 264055].

Views: 111

Nathan Radcliffe,1 John Berdahl,2 Mitchel Ibach,2 Justin Schweitzer,2 Jason Levine,3 Sean McCafferty3

1New York Eye Surgery Center, New York, NY, USA; 2Vance Thompson Vision, Sioux Falls, SD, USA; 3Arizona Eye Consultants, Tucson, AZ, USA

Correspondence: Sean McCafferty
Arizona Eye Consultants, 6422 E. Speedway Blvd, Tucson, AZ 85710, USA
Tel +1 (520) 327-3487

Purpose: To evaluate intraocular pressure (IOP) reduction measured by a Goldmann applanation tonometer (GAT) prism and a modified surface Goldmann (CATS) prism with the institution of a topical prostaglandin analog (PGA) or alternatively a topical beta blocker.
Design: Prospective, open-label, randomized, controlled, and reference device comparison.
Methods: Thirty-six (36) treatment naïve glaucoma patients (72 eyes) were randomized equally to treatment with latanoprost 0.005% or timolol maleate 0.5%. Each patient underwent IOP measurement with standard GAT and CATS prisms before and at 1, 3, and 6 months of treatment. Central corneal thickness (CCT) and corneal hysteresis (CH) were also measured. Medication response was defined as a 20% reduction in IOP from baseline.
Results: The CATS prism demonstrated the IOP reduction with topical latanoprost at a mean of 1.9 mmHg lower than the IOP measured with GAT (p=0.01). The CATS and GAT prisms detected no difference in IOP reduction with timolol (p=0.23). The number of latanoprost treatment non-responders was reduced from 36.1% measured with GAT to 13.8% when measured with the CATS prism (p=0.005). Timolol indicated no difference in the treatment non-response rate at 22.2% (p=0.999). CH increased significantly with latanoprost treatment by an average of 0.55 mmHg (p=0.014) and remained unchanged with timolol at − 0.014 mmHg (p=0.68).
Discussion: IOP reduction and responder rates were increased when measured with a CATS prism in patients using latanoprost and not with timolol use. Latanoprost-induced alterations in corneal biomechanics may dampen the actual IOP reduction measured with a standard GAT prism.
Clinical Trial Registration: NCT04178863.

Keywords: glaucoma, prostaglandins, IOP, tonometer, corneal biomechanics, timolol, latanoprost

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]